Compare Citius Pharmaceuticals Inc (CTXR) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Roundhill NVDA WeeklyPay ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Roundhill NVDA WeeklyPay ETF trades at $37. The key difference: Roundhill NVDA WeeklyPay ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | NVDW | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.82 | $53.42 |
52-Week Low | $0.53 | $31.88 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
NVDW trades at $35.81, down 4.66% over the past day, with technical indicators showing mixed signals—bullish oscillators but bearish moving averages. The stock has a history of frequent dividend payments, with recent payouts ranging from $0.21 to $0.48 per share. Key support is near $35, while resistance levels start at $38.
The outlook hinges on NVDW's ability to maintain its dividend stream amid market volatility. Risks include dependency on underlying asset performance and payout fluctuations. Upside potential exists if technical resistance is broken, but investors should monitor earnings stability and broader market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
